Apolipoprotein C3 as A Paradoxical Inhibitor of Platelet Aggregation and Thrombosis – JTH
Journal of Thrombosis and Haemostasis (JTH) shared on LinkedIn about a recent article by Waltraud C. Schrottmaier et al, adding:
”Elevated Levels of Apolipoprotein C3 Impair Platelet Function and Reduce Thrombosis
ApoC3, a known cardiovascular risk factor, paradoxically acts as a lipoprotein-derived inhibitor of platelet aggregation and thrombosis by modulating AKT and VASP signaling and disrupting actin cytoskeleton remodeling, potentially counterbalancing its proatherogenic effects in hyperlipidemia.”
Title: Elevated levels of apolipoprotein C3 impair platelet function and reduce thrombosis
Authors: Waltraud C. Schrottmaier, Julia B. Kral-Pointner, Marion Mussbacher, Manuel Salzmann, Bernhard Hochreiter, Anita Pirabe, Theresa Reiter, Sigrun Badrnya, Johannes A. Schmid, Ivo Volf, Alice Assinger
Read the Full Article on JTH
Stay updated on all scientific advances with Hemostasis Today.
-
Apr 14, 2026, 17:32Denise M.: Surviving Sepsis 2026 – The Upstream Revolution
-
Apr 14, 2026, 17:23Meghanath Yenni։ What’s New in Acute Ischemic Stroke in 2026
-
Apr 14, 2026, 17:11Phil Spinella: What Dose of TXA for Children With Severe Traumatic Bleeding Should You Use?
-
Apr 14, 2026, 17:08Abdulrahman Katib: How Endovascular Stenting Is Transforming the Treatment of Severe PTS
-
Apr 14, 2026, 17:00Anna A. Avagyan: Glad to Be Part of EHA Pediatric Hematology-Oncology Course
-
Apr 14, 2026, 16:58Ney Carter Borges: NLRP3 Inhibition in Atherosclerosis – Early Clinical Signal Beyond Lipids
-
Apr 14, 2026, 16:56Saskia Middeldorp: Key Takeaways from the 2026 ACC/AHA Guideline on Acute PE
-
Apr 14, 2026, 16:54Chokri Ben Lamine: Extracorporeal Photopheresis for aGVHD cGVHD Post-SCT – 50 Pearls
-
Apr 14, 2026, 16:49Ahmed Magdi Omar: Key Takeaways From the Latest 2026 Guidelines on Antiplatelet Therapy in AIS